ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0263

Roxadustat Increases Hemoglobin in Anemic Non-Dialysis-Dependent (NDD) CKD Patients Independent of Inflammation

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Pollock, Carol A., The University of Sydney, Sydney, New South Wales, Australia
  • Roger, Simon D., Renal Unit, Gosford Hospital, Gosford, New South Wales, Australia
  • Manllo-Karim, Roberto, Gamma Medical Research, McAllen, Texas, United States
  • Pola, Maksym, Clinical Research, AstraZeneca, Warsaw, Poland
  • Tham, Stefan, Clinical Research, AstraZeneca, Gothenburg, Sweden
  • Yu, Kin-Hung Peony, FibroGen Inc., San Francisco, California, United States
  • El-Shahawy, Mohamed A., Keck-USC School of Medicine, Los Angeles, California, United States
Background

Inflammation is a common cause of decreased responsiveness to erythropoiesis-stimulating agents. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, treats anemia by inducing endogenous erythropoietin production and increasing iron utilization via reducing hepcidin. Roxadustat efficacy has been shown in those with inflammation, as defined by baseline (BL) elevation of high sensitivity C-reactive protein (hsCRP). This pooled analysis explored the efficacy of roxadustat in correcting Hb in NDD-CKD patients across the spectrum of BL hsCRP values.

Methods

Data from three randomized Phase 3 pivotal trials in anemic patients with Stage 3–5 NDD-CKD were pooled and the efficacy of roxadustat in increasing hemoglobin (Hb) from BL was assessed. hsCRP concentration was used as a marker of inflammation; patients with hsCRP >5 mg/L were considered to have inflammation at BL. Mean Hb change from BL (CFB) to Weeks 28–52 was summarized by baseline hsCRP quintile. Roxadustat dose requirements at Week 24 were based on mean weekly dose in mg per kg of mean BL weight.

Results

Overall, 1691 roxadustat-treated NDD-CKD patients were assessed and had a mean BL hsCRP of 7.4 mg/L. Mean BL Hb measures were similar across the hsCRP quintiles (range 9.0–9.2 g/dL). In patients with BL inflammation (n=523), mean Hb CFB to Weeks 28–52 was 1.95 g/dL with roxadustat. Mean Hb CFB to Weeks 28–52 was also similar across all hsCRP quintiles in roxadustat-treated patients (Figure). Mean weekly roxadustat doses at Week 24 for baseline hsCRP quintiles 1 through to 5 were comparable at 3.2, 2.9, 2.5, 3.0, and 3.0 mg/kg, respectively.

Conclusion

Roxadustat increased Hb in anemic NDD-CKD patients independent of inflammation.

Funding

  • Commercial Support